|
The number of rats developing SRS
|
The time to development of SRS (days)
|
The mean number of seizures (seizures/day)
|
The mean seizure duration (sec/seizure)
|
Control siRNA + sham
|
0 (18)
|
0
|
0
|
0
|
NLRP3 siRNA+ sham
|
0 (18)
|
0
|
0
|
0
|
Control siRNA + SE
|
18 (18)
|
14.8 ± 5.5
|
7.58 ± 1.09
|
26.62 ± 6.94
|
NLRP3 siRNA+ SE
|
12 (18)a
|
27.5 ± 9.3a
|
1.34 ± 0.44a
|
10.48 ± 2.76a
|
(B) Results from rats after 6 weeks of treatment with caspase-1 siRNA or control siRNA
|
|
The number of rats developing SRS
|
The time to development of SRS (days)
|
The mean number of seizures (seizures/day)
|
The mean seizure duration (sec/seizure)
|
Control siRNA + sham
|
0 (18)
|
0
|
0
|
0
|
Caspase-1 siRNA + sham
|
0 (18)
|
0
|
0
|
0
|
Control siRNA+ SE
|
17 (18)
|
16.6 ± 6.1
|
9.02 ± 1.56
|
23.67 ± 5.90
|
Caspase-1 siRNA+ SE
|
11 (18)a
|
26.8 ± 9.1a
|
2.40 ± 0.78a
|
8.21 ± 2.66a
|